OncoMatch/Clinical Trials/NCT07284927
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
Is NCT07284927 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies LV009 for non-hodgkin lymphoma.
Treatment: LV009 — This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory CD19-positive hematolymphoid malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 overexpression (positive)
confirmed diagnosis of CD19-positive hematolymphoid malignancy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: relapsed or refractory disease
Meets the National Comprehensive Cancer Network (NCCN) criteria for relapsed or refractory disease
Cannot have received: CAR-T cell therapy
Patients who have received CAR-T therapy or other genetically modified cell therapies prior to screening.
Lab requirements
Blood counts
ALC ≥ 0.5 × 10⁹/L; Platelet count ≥ 50 × 10⁹/L; CD3-positive T-cell count ≥ 150 cells/μL
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
adequate cardiopulmonary function
Adequate hepatic, renal, and cardiopulmonary function; ALC ≥ 0.5 × 10⁹/L; Platelet count ≥ 50 × 10⁹/L; CD3-positive T-cell count ≥ 150 cells/μL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07284927 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify